Current oral medications often take weeks to months to exhibit their maximum efficacy in migraine patients. However, a few studies have indicated that calcitonin gene-related peptide (CGRP) targeted-monoclonal antibodies may act quickly against migraines . A recent study has examined whether atogepant, a CGRP receptor antagonist, could act rapidly, reduce migraines, and improve the quality of life in patients.
The study included three clinical trials involving adults aged 18 to 80 with episodic or chronic migraines or previous treatment failures with two to four oral preventives. The study found that atogepant significantly lowered the risk of migraines on the first day of treatment compared to a placebo (odds ratios observed from each study: 0.39, 0.53, and 0.63). Additionally, patients treated with atogepant experienced fewer migraines per week and month, with improved functional…
